注射用丹酚酸A防治肝纤维化的实验研究

Effects of salvianolic acid A injection on CCl_4 induced hepatocyte injury and hepatic fibrosis in rats

目的探讨注射用丹酚酸A抗肝纤维化的作用,为丹酚酸A的临床应用提供理论依据。方法采用CCl4体外诱导肝细胞损伤,观察丹酚酸A对肝细胞活性及其细胞培养上清液ALT、AST、LDH水平和细胞裂解液中SOD活性和MDA含量的变化;另采用皮下注射CCl4诱导大鼠肝纤维化模型,观察丹酚酸A对肝纤维化大鼠血清LN、HA、SOD和MDA含量的影响以及肝脏组织病理改变情况。结果与模型对照组比,丹酚酸A高、低剂量组和Vit E组的细胞存活率显著提高(P<0.01),丹酚酸A高剂量组ALT、AST和LDH活性显著降低(P<0.01),丹酚酸A高剂量组和Vit E组SOD活性明显升高(P<0.05),MDA含量显著降低(P<0.05);体内试验发现,与模型对照组比,丹酚酸A高剂量组纤维化大鼠的血清LN和HA水平显著降低(P<0.05),高、低剂量组SOD活性显著升高(P<0.05,P<0.01),MDA含量显著降低(P<0.01,P<0.05),并能改善肝脏病理形态。结论注射用丹酚酸A可通过抗脂质过氧化作用,起到保护肝细胞,减轻肝纤维化的作用。

Objective To study on the anti-hepatic fibrosis effects of salvianolic acid A injection （SAA）, and further to provide the theoretical basis for the clinical application .Methods Using CCl4 induced hepatocyte injury in vitro, the hepatocyte viability , the levels of ALT , AST and LDH in cell culture supernatants and the levels of SOD and MDA in cell lysates were detected .In addition , the hepatic fibrosis rat model was made by subcutaneous injection of CCl 4 , the serum LN, HA, SOD and MDA levels were detected and the pathological changes in liver tissue were also observed . Results Compared with model group , the hepatocyte viability in SAA high or low dose group and Vit E group were significantly increased （P 〈0.01）, and the activities of ALT, AST and LDH in SAA high dose group were significantly lowed （ P ＆lt;0.01 ） .The activity of SOD in SAA high dose group and Vit E group was significantly increased （ P ＆lt;0.05）, while MDA content was decreased （P ＆lt;0.05）.Vivo test showed that the levels of serum LN and HA in SAAhigh dose group were significant lower than those of hepatic fibrosis rat model group （P ＆lt;0.05）.Moreover, the activity of SOD in SAA high or low dose group was significantly increased （P ＆lt;0.05, P ＆lt;0.01）, while MDA content was lowed （P ＆lt;0.05, P ＆lt;0.01）, and can improve the pathological of liver tissues .Conclusions SAA injection can anti-lipid peroxidation and thereby protect hepatocyte and reduce hepatic fibrosis .